These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 28292270)

  • 1. Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema.
    Minami Y; Nagaoka T; Ishibazawa A; Yoshida A
    BMC Ophthalmol; 2017 Mar; 17(1):28. PubMed ID: 28292270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion: a prospective observational study.
    Minami Y; Nagaoka T; Ishibazawa A; Yoshida A
    BMC Ophthalmol; 2017 Jun; 17(1):90. PubMed ID: 28610573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SHORT-TERM EFFECT OF INTRAVITREAL RANIBIZUMAB THERAPY ON MACULAR EDEMA AFTER BRANCH RETINAL VEIN OCCLUSION.
    Minami Y; Nagaoka T; Ishibazawa A; Yoshida A
    Retina; 2016 Sep; 36(9):1726-32. PubMed ID: 26866527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Hirabayashi K; Nagaoka T; Takamura Y; Sugimoto M; Murata T
    Jpn J Ophthalmol; 2017 Jan; 61(1):51-60. PubMed ID: 27730425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between characteristics of foveal cystoid spaces and short-term responsiveness to ranibizumab for diabetic macular edema.
    Murakami T; Suzuma K; Uji A; Yoshitake S; Dodo Y; Fujimoto M; Yoshitake T; Miwa Y; Yoshimura N
    Jpn J Ophthalmol; 2018 May; 62(3):292-301. PubMed ID: 29460019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optical coherence tomography biomarkers DROL, PROS, SND, hyperreflective walls of foveal cystoid spaces as predictors of central macular thickness and visual acuity in diabetic macular edema treated with intravitreal ranibizumab.
    Sardana A; Singh K; Singh A; Singh VK
    Indian J Ophthalmol; 2024 May; 72(5):722-727. PubMed ID: 38648434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anatomical and functional responses in eyes with diabetic macular edema treated with "1 + PRN" ranibizumab: one-year outcomes in population of mainland China.
    Lai K; Huang C; Li L; Gong Y; Xu F; Zhong X; Lu L; Jin C
    BMC Ophthalmol; 2020 Jun; 20(1):229. PubMed ID: 32539744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice.
    Sato S; Shinoda H; Nagai N; Suzuki M; Uchida A; Kurihara T; Kamoshita M; Tomita Y; Iyama C; Minami S; Yuki K; Tsubota K; Ozawa Y
    Medicine (Baltimore); 2017 Apr; 96(16):e6459. PubMed ID: 28422835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience.
    James DGP; Mitkute D; Porter G; Vayalambrone D
    Asia Pac J Ophthalmol (Phila); 2019; 8(3):200-205. PubMed ID: 31165603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography.
    Hu Y; Wu Q; Liu B; Cao D; Dong X; Zhang L; Li T; Yang X; Yu H
    Graefes Arch Clin Exp Ophthalmol; 2019 Dec; 257(12):2613-2621. PubMed ID: 31529324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VISUAL AND MORPHOLOGIC OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR DIABETIC MACULAR EDEMA BASED ON OPTICAL COHERENCE TOMOGRAPHY PATTERNS.
    Seo KH; Yu SY; Kim M; Kwak HW
    Retina; 2016 Mar; 36(3):588-95. PubMed ID: 26398695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema.
    Morioka M; Takamura Y; Yamada Y; Matsumura T; Gozawa M; Inatani M
    Graefes Arch Clin Exp Ophthalmol; 2018 Dec; 256(12):2301-2307. PubMed ID: 30238189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
    Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
    Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
    Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
    Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-Year Functional and Morphological Prognosis After Intravitreal Injection Treatments According to Different Morphological Patterns of Diabetic Macular Edema in Real-Life: MARMASIA Study Group Report No.13.
    Limon DU; Kaplan FB; Saygın I; Önder Tokuç E; Kutlutürk Karagöz I; Kanar HS; Sevik MO; Yayla U; Çelik E; Sönmez A; Aykut A; Kumral Türkseven E; Erçalık NY; Oncu Aydın Ö; Bozkurt E; Aydoğan T; Emengen EB; Özkaya A; Açıkalın Öncel B; Yenerel NM; Şahin Ö; Karabaş L
    Semin Ophthalmol; 2024 Aug; 39(6):460-467. PubMed ID: 39087722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema.
    Cicinelli MV; Cavalleri M; Querques L; Rabiolo A; Bandello F; Querques G
    Br J Ophthalmol; 2017 Dec; 101(12):1689-1693. PubMed ID: 28432109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema.
    Moshfeghi AA; Shapiro H; Lemmon LA; Gune S
    Ophthalmol Retina; 2018 Feb; 2(2):86-90. PubMed ID: 31047350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and functional assessment after intravitreal injection of ranibizumab in diabetic macular edema.
    Fu Y; Wang P; Meng X; Du Z; Wang D
    Doc Ophthalmol; 2017 Dec; 135(3):165-173. PubMed ID: 28756595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.